Immune Biomarkers of Mechanism of Action of Epcoritamab (Epcor) Plus Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) in Frontline DLBCL
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-200395
Abstract: Background: Epcor, a subcutaneous CD3xCD20 bispecific antibody, is approved as monotherapy for adults with relapsed or refractory DLBCL after ≥2 lines of systemic therapy. Combining epcor with antineoplastic agents that have complementary mechanisms of action… read more here.
Keywords: treatment; pola; mrd negativity; epcor ... See more keywords
primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-466
Abstract: INTRODUCTION: Patients (pts) with relapsed/refractory (R/R) follicular lymphoma FL have limited second line (2L) treatment options, rituximab and lenalidomideR2being the only 2L alternative to immunochemotherapy-based therapy. Epcoritamab (epcor), a CD3xCD20 bispecific antibody, is approved for… read more here.
Keywords: refractory follicular; trial; follicular lymphoma; epcor ... See more keywords
Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.7029
Abstract: 7029 Background: Epcor is the only SC CD3xCD20 bispecific antibody approved for R/R DLBCL. In initial protocols, hospitalization after the 1st full dose of epcor was required to monitor patients (pts) for and characterize CRS.… read more here.
Keywords: 1st full; full dose; epcor; crs ... See more keywords